![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » White House Sends Drug Pricing Wish List to Congress
White House Sends Drug Pricing Wish List to Congress
![WhiteHouse.gif](https://www.fdanews.com/ext/resources/test/WhiteHouse.gif?t=1581355320&width=430)
March 20, 2020
President Trump sent a list of “principles” to lawmakers outlining what the administration wants to see in a drug pricing bill as a Senate bill with some of the president’s ideas moves toward passage this spring.
The administration called for a cap on Medicare Part D beneficiary annual and monthly out-of-pocket pharmacy expenses.
The White House has previously endorsed S. 2543, a bipartisan proposal introduced by Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.), but the new White House wish list goes beyond the scope of that bill. The Grassley-Wyden bill only provides for an annual cap on Part D expenses.
The administration’s proposed budget for fiscal 2021 projects that HHS will save $135 billion over 10 years as a result of drug pricing reform.
Upcoming Events
-
21Oct